Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 6/2015

01-06-2015 | Editorial

How do we conquer the recurrence of HCC?

Author: Kazuhiro Nouso

Published in: Journal of Gastroenterology | Issue 6/2015

Login to get access

Excerpt

According to recent advancements in imaging modalities and due to the prevalence of surveillance systems for hepatocellular carcinoma (HCC), early detection of HCC has been achieved, and the proportion of patients who can receive local ablation therapy or surgical resection is increasing. Although tumors seem to be treated completely, recurrence of HCC has been frequently observed at an annual incidence rate of approximately 20 %. To achieve long survival of patients with HCC, suppression of recurrence is mandatory. …
Literature
1.
Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44(4):891–5 (Epub 2006/09/29).PubMedCrossRef
2.
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2014. doi:10.​1007/​s00535-014-0956-9.
3.
Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2014. doi:10.​1007/​s00535-014-0996-1.
4.
Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191 (Epub 2013/04/17).PubMedCentralPubMedCrossRef
5.
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. New Engl J Med. 1996;334(24):1561–7 (Epub 1996/06/13).PubMedCrossRef
Metadata
Title
How do we conquer the recurrence of HCC?
Author
Kazuhiro Nouso
Publication date
01-06-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 6/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-1003-6

Other articles of this Issue 6/2015

Journal of Gastroenterology 6/2015 Go to the issue

Erratum

Erratum to: Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis

Original Article—Liver, Pancreas, and Biliary Tract

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial

Original Article—Liver, Pancreas, and Biliary Tract

Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients

Review

Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage

Original Article—Liver, Pancreas, and Biliary Tract

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA

Review

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits